CTOs on the Move

Dicerna

www.dicerna.com

 
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dicerna.com
  • 33 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.621.8097

Executives

Name Title Contact Details

Funding

Dicerna raised $70M on 03/30/2017
Dicerna raised $100M on 10/29/2018

Similar Companies

Lexigen

Lexigen is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Network

Health Network is a Cranston, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glenmark Generics Limited

Glenmark Generics Limited is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Pharmacy Concepts

Advanced Pharmacy Concepts is a North Kingstown, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.